Rescheduling happened on paper. The instructions never showed up.
Clint Kellum, who runs California’s Department of Cannabis Control, told the state’s Cannabis Advisory Committee that DEA headquarters has given California zero formal implementation guidance on medical marijuana rescheduling. Not vague guidance. Not slow guidance. Zero. This after repeated requests from California, including coordinated outreach with regulators in other states.
Nine months after the DEA order took effect, the country’s largest legal cannabis market is operating on guesswork. If you run a licensed cannabis business anywhere in America, this is your problem too.
Zero Guidance, Plenty of Data Requests
Here is the part that should make every operator’s skin crawl. While DEA stays silent on implementation, the agency is actively requesting data from California about its medical cannabis program, including production and dispensing figures. California is being asked to hand over operational intelligence to a federal agency that will not explain what it plans to do with it or how operators should prepare for what comes next.
California pushed back the right way. Kellum said the department asked DEA what the data will actually be used for and offered to walk the agency through California’s licensing structure before handing anything over. So far, no explanation has arrived.
There is a real complication underneath. California’s market blends medical and adult use activity in ways that do not map cleanly onto DEA’s request. Identifying as a medical patient carries little practical incentive when adult use products are available to anyone 21 and older. The state’s official medical figures do not reflect the full scope of medical cannabis activity on the ground. Handing over numbers without context risks those numbers being misread by people who do not understand the market.
A federal agency is collecting data from an industry it refuses to instruct. Sit with that for a moment.
Inspections Without a Playbook
Businesses that registered with DEA under the new Schedule III framework are not operating in a vacuum. Kellum told the advisory committee that other states are already seeing DEA inspections at marijuana businesses that applied for federal protections.
Two details stand out. First, DEA appears to be prioritizing states with clean, standalone medical programs over states like California, where medical and adult use licensing overlap. California is a “mixed” state in this context, one DEA seems to be treating differently, and possibly more slowly, than states with simpler structures.
Second, there is regional variation in what inspectors actually ask. Reporting from Marijuana Moment has found DEA officials posing different sets of follow up questions to cannabis businesses depending on location, rather than applying one consistent national standard. Two businesses in two states, both registered under the same federal framework, face entirely different inspection experiences.
Registering with the DEA was supposed to bring order and legitimacy. What operators got is a patchwork of inconsistent inspections that vary by which regional office knocks on the door.
California Refuses to Guess
To his credit, Kellum is refusing to play the guessing game. His words to the committee: “The last thing what we want to do is try to be guessing what they are going to be doing, and then trying to make changes that have widespread effects across our market, and then ultimately to find out that there is some sort of different path or vision.”
Translation: California will not rebuild its regulatory framework around assumptions and then rebuild it again when DEA finally speaks. The department made narrower moves, like emergency rules in May letting businesses change license designations to qualify for federal benefits. Broader shifts are on pause until something concrete arrives.
DCC spokesperson Jordan Traverso echoed it: the goal is to stay responsive “without getting in the way of, or projecting certainty onto, a process that remains outside state control.” In plain terms, California will not pretend to know something it does not.
The Four Open Federal Questions
Kellum identified four specific developments California is tracking before it considers further material changes:
- Formal implementation guidance directly from DEA headquarters.
- The outcome of DEA’s broader administrative hearing on rescheduling marijuana beyond state licensed medical cannabis.
- Guidance from the IRS on how Section 280E tax relief applies to businesses with both medical and adult use operations. Treasury said back in April it would issue guidance. Operators are still waiting.
- The results of pending litigation challenging the rescheduling order itself.
Each carries real financial weight. The IRS question alone determines whether mixed market operators get relief from 280E, the provision blocking standard business deductions.
Congress is feeling the pressure too. In August, a bipartisan House group led by Rep. Dina Titus sent a letter to President Trump and three cabinet secretaries asking for clarity on worker protections, patient rights, insurance coverage, and how the DEA registration system will actually function. They asked for answers by September 30. That deadline is one week away.
Vermont Cannabis Control Board chair James Pepper said the quiet part out loud earlier this year: “None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock.” If California, with its scale and staff, cannot get DEA on the phone, smaller state programs are not faring better.
The Operator Takeaway
The real exposure for your business lives in the gap between rescheduling on paper and rescheduling in practice. A schedule change sounded like resolution. In reality it opened a long list of open questions that federal agencies have been slow to answer.
So operate accordingly. Document everything, because inconsistent regional inspections mean your records are your defense. Do not build compliance strategy around assumptions about what DEA might eventually say. Watch the September 30 congressional letter deadline for any movement. And understand the fundamental dynamic: the agency asking for your data has not told you the rules. Plan like it stays that way until proven otherwise.
This is the Beard Bros beat and we will keep covering it. The industry deserves better than silence from the agency that demanded its paperwork.
For the courtroom update, see the DEA judge pausing cannabis rescheduling ahead of the October 13 deadline. For operator sentiment on the ground, see why two thirds of Missouri cannabis operators said no to the DEA.
FAQs
1. 1. What did California’s top cannabis regulator say?
DCC director Clint Kellum told the state’s Cannabis Advisory Committee that DEA headquarters has given California zero formal implementation guidance on medical marijuana rescheduling, despite repeated requests.
2. 2. Why is the DEA collecting data while giving no guidance?
The agency is requesting production and dispensing figures from California’s medical program without explaining what it will do with the data. A federal agency is collecting operational intelligence from an industry it refuses to instruct.
3. 3. How did California push back?
Kellum said the department asked the DEA what the data will actually be used for and offered to walk the agency through California’s licensing structure first. No explanation has arrived.
4. 4. Why are California’s numbers tricky for the DEA?
The state blends medical and adult use activity in ways that do not map cleanly onto the DEA’s request. Official medical figures understate real medical cannabis activity, so raw numbers risk being misread.
5. 5. What are other states experiencing?
Some states are already seeing DEA inspections at businesses that registered under the Schedule III framework, with the DEA prioritizing states that have clean standalone medical programs and inspectors asking different questions by region.
Source
Original reporting by Beard Bros Pharms (no named byline on the source page): Medical Marijuana Was Rescheduled. States Still Don’t Know the Rules.